# Ozempic and Wegovy Reduce Risk of Severe COVID in Individuals with Obesity, According to Harvard Study – Obesity is a significant risk factor for severe COVID-19 complications. – A recent study conducted by Harvard researchers found that medications like Ozempic and Wegovy can potentially reduce the risk of severe COVID-19 in individuals with obesity. – These medications are primarily used for weight management and can have the added benefit of improving COVID-19 outcomes in this particular population. – The study highlights the importance of weight management in reducing the risk of severe COVID-19 in individuals with obesity. ### Hot Take The findings of the Harvard study shed light on the potential benefits of medications like Ozempic and Wegovy in reducing the risk of severe COVID-19 among individuals with obesity. Weight management plays a crucial role in overall health and well-being, and these medications can be a valuable tool in improving outcomes for individuals at higher risk. It is essential for individuals to explore all available options, including medication and lifestyle changes, to support their weight loss journey and overall health. Contact Mindful Evolution on our website https://yourmindfulevolution.com or call or text us at 954-639-9960 for personalized guidance on weight management strategies. Weight loss disclaimer: Individual results may vary. Our services are available through telehealth in the states of Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia.